Trial Profile
RESOLUTE-KOREA Registry - Registry to Evaluate the Efficacy of Zotarolimus-eluting Stent.
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 30 Sep 2017
Price :
$35
*
At a glance
- Drugs Zotarolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms RESOLUTE-KOREA
- 30 Aug 2017 Results comparing biodegradable-polymer biolimus A9-eluting stents and durable polymer drug-eluting stents from this and other registries in Korea, presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology
- 26 Aug 2009 New trial record